Israeli food-tech innovator Amai Proteins has achieved a significant regulatory milestone with the approval of its groundbreaking sweet protein, Sweelin, for sale in Singapore. This marks the first time a precision fermentation-derived sweet protein has received authorization in the city-state, positioning Singapore as a key market in the global push for healthier food and beverage options. The approval from the Singapore Food Agency (SFA) comes just three months after Amai Proteins garnered similar clearance from the U.S. Food and Drug Administration (FDA), underscoring the company’s rapid progress and the growing international acceptance of its novel sweetening technology.
The introduction of Sweelin into Singapore’s market directly addresses the nation’s ambitious agenda to curtail sugar consumption, a public health priority driven by rising rates of diet-related diseases. Amai Proteins’ proprietary technology, which leverages artificial intelligence and precision fermentation, offers a sustainable and healthier alternative to conventional sugars and artificial sweeteners.
A Leap Forward in Sweetener Technology
Sweelin, Amai Proteins’ flagship product, is a calorie-free protein inspired by monellin, a naturally occurring sweet protein found in the serendipity berry. The company’s proprietary AI-powered Pro³ Platform was instrumental in developing Sweelin into a highly concentrated sweetener, boasting a sweetness intensity approximately 3,000 times that of sucrose. This extraordinary potency allows for a significant reduction in the amount of sweetener needed in food and beverage formulations, while delivering a clean taste profile without the bitter aftertaste often associated with other high-intensity sweeteners.
The production process for Sweelin involves precision fermentation, utilizing a modified yeast strain, Komagataella phaffii. This is the same bio-engineering marvel that enables the creation of heme, the key ingredient that gives the Impossible Burger its meaty characteristics. This advanced biotechnological approach not only ensures a consistent and scalable supply of the sweet protein but also offers substantial environmental benefits.
Environmental and Health Advantages of Sweelin
Amai Proteins highlights the impressive sustainability credentials of Sweelin. The company estimates that replacing added sugar with Sweelin can lead to a reduction in the product’s climate footprint by as much as 98%. To illustrate this impact, a single teaspoon of Sweelin is equivalent to 12 kilograms of sugar in sweetness. This substitution conserves vast amounts of resources: enough water to fill 150 bathtubs, energy equivalent to powering a clothes dryer for 30,000 hours, and land area spanning two football fields. These figures underscore the potential of Sweelin to contribute significantly to a more sustainable food system.
Crucially, Sweelin has demonstrated a neutral impact on blood glucose and insulin levels, as confirmed by controlled clinical trials. This makes it a particularly attractive option for consumers managing their sugar intake and for those seeking to prevent or manage conditions like type 2 diabetes. Furthermore, a comprehensive study conducted last year provided robust evidence of Sweelin’s complete digestibility, with no adverse effects observed even at the highest tested dosages, reassuring consumers and regulatory bodies alike about its safety profile.
Strategic Market Entry and Global Ambitions
The regulatory approval in Singapore is a strategic stepping stone for Amai Proteins. The company views Singapore as a vital gateway to the burgeoning Asia-Pacific market, where consumer demand for healthier food options is rapidly accelerating. The approval follows closely on the heels of the U.S. FDA clearance, where Sweelin can be marketed as "serendipity berry sweet protein," a clear and consumer-friendly designation that appeals to individuals actively seeking next-generation sugar alternatives and products aligned with GLP-1 friendly diets.
Amir Guttman, CEO of Amai Proteins, expressed his enthusiasm for the Singaporean endorsement: "Singapore continues to demonstrate global leadership in food innovation through its forward-looking regulatory framework. We are honoured that Sweelin is the first precision fermentation-derived sweet protein approved in this ecosystem. This approval validates our regulatory strategy and creates exciting opportunities for commercialisation throughout Singapore and the Asia-Pacific region."
Tapping into Asia-Pacific’s Sugar Reduction Momentum
The Asia-Pacific region presents a fertile ground for Amai Proteins’ innovative sweetener. A growing awareness of the health risks associated with excessive sugar consumption is driving a significant shift in consumer preferences. Research from ADM in 2023 revealed that a substantial 77% of Asia-Pacific consumers are actively trying to reduce their sugar intake, while 82% still prioritize products that offer appealing and interesting flavors. This indicates a clear market need for sugar substitutes that do not compromise on taste.
Further reinforcing this trend, a 2025 survey by Ingredion found that 80% of Asia-Pacific residents are willing to pay a premium of up to 30% for products explicitly labeled as "no added sugar" or "reduced sugar." This willingness to invest in healthier options signals a robust market opportunity for companies like Amai Proteins. Data from Cargill also indicates a significant rise in the adoption of alternative sweeteners in beverage launches across the region, increasing from 18% in 2017 to 29% in 2024, showcasing a clear market shift.
Singapore’s government has been at the forefront of these public health efforts. With over two in five citizens being overweight or obese and more than 11% living with diabetes, the nation has implemented proactive measures to combat these health challenges. The introduction of the Nutri-Grade labelling system in 2022, which categorizes food and beverages based on their sugar and saturated fat content, has been instrumental in guiding consumers towards healthier choices. The impact of these initiatives is already evident; the Ministry of Health reported a decline in the median sugar level of pre-packaged beverages from 7.1% in 2017 to 4.6% in 2023, and a reduction in average daily sugar intake from 60g in 2018 to 56g in 2022.
A Timeline of Innovation and Regulatory Success
Amai Proteins, founded a decade ago by Ilan Samish, has been steadily building its technological foundation and product pipeline. The development of the Pro³ Platform, a sophisticated AI-driven system, has been central to its strategy of creating a diverse range of "designer sweet proteins." This platform allows for the rapid identification, optimization, and production of novel protein-based sweeteners tailored for various food and beverage applications.
The journey to regulatory approval has been a carefully orchestrated process. The U.S. FDA approval in March 2024 marked a pivotal moment, opening the door to one of the world’s largest consumer markets. This success paved the way for the subsequent application and approval in Singapore, demonstrating a consistent and effective regulatory engagement strategy. The timeline of these approvals highlights the company’s agility and its commitment to bringing its innovative solutions to market efficiently.
Broader Implications for the Food Industry and Public Health
The advent of precision fermentation-derived sweet proteins like Sweelin represents a paradigm shift in the food industry’s approach to sugar reduction. Beyond offering a healthier alternative, these novel ingredients have the potential to disrupt traditional sugar production and consumption patterns. The environmental benefits associated with their production are also critically important in an era of increasing climate consciousness.
For food and beverage manufacturers, Sweelin offers a versatile and cost-effective solution to reformulate products, meet evolving consumer demands, and comply with regulatory pressures. The ability to replace a significant portion of added sugar without compromising taste or incurring prohibitive costs is a compelling proposition. Amai Proteins’ focus on competitive pricing further enhances its market appeal, particularly in price-sensitive emerging markets.
The long-term implications for public health are also significant. By providing a viable and appealing alternative to sugar, Sweelin can contribute to reducing the global burden of obesity, diabetes, and other non-communicable diseases. The clear labeling in markets like the U.S. and the supportive regulatory environment in Singapore are crucial for consumer education and adoption.
Future Outlook and Strategic Partnerships
Looking ahead, Amai Proteins is poised to scale up its commercial activities. The company is actively seeking strategic partnerships with food and beverage manufacturers across Singapore and the broader Asia-Pacific region. These collaborations will be essential for the successful integration of Sweelin into a wide range of consumer products, from dairy alternatives and soft drinks to snacks and condiments.
The company’s ongoing work with investors and strategic partners is aimed at supporting large-scale production capabilities and facilitating a robust commercial rollout. The success in Singapore is expected to catalyze further regulatory approvals in other key markets, expanding the global reach of Sweelin and Amai Proteins’ innovative sweet protein portfolio. The company’s vision extends to developing a comprehensive suite of designer sweet proteins, each tailored to specific applications and consumer needs, further solidifying its position as a leader in the future of sweetening.
